Fig. 1From: Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancerComparison of EGFR, BCL-2, and BCL-XL expression levels. Seven PDX models of TNBC were immuno-stained for EGFR (a), BCL-2 (b), and BCL-XL (c). Representative immuno-stains are shown. The IHC results were semi-quantitated via H-score assessment and summarized in Table 2. Scale bar, ~ 200 μmBack to article page